Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2017-04-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于预计2017年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the fiscal year 2017. It includes details about the nature of the transactions, the parties involved, approval procedures, and the impact on the company. The document is relatively short (3125 characters) and focuses on disclosure of related party transactions rather than presenting financial statements or detailed financial performance. It does not contain comprehensive financial data or management discussion of results. This type of disclosure is typical of regulatory announcements about related party transactions rather than a full financial report or management report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2017-04-16 Chinese
关于对部分暂时闲置募集资金及公司自有资金进行现6管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the management of temporarily idle raised funds and company-owned funds through cash management. It details the approval process, amounts involved, purpose, risk control measures, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial results but is a formal disclosure about the company's cash management plans and approvals. It is not an annual report, interim report, earnings release, or any detailed financial report. It is also not a regulatory certification or officer attestation. The document is a regulatory announcement about the company's capital management activities, specifically the use of idle raised funds and own funds for cash management. This fits best under the category of Capital/Financing Update (CAP). The document length is 3146 characters, which is relatively short but contains substantive information about capital management rather than just a notice of report publication or a simple regulatory filing. Therefore, the classification is CAP with high confidence.
2017-04-16 Chinese
关于变更募集资金投资项目实施方案的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about changes to the implementation plan of its fundraising investment projects. It discusses the original and new investment projects, amounts, reasons for changes, project details, market prospects, risk warnings, approvals, and opinions from independent directors, supervisors, and sponsors. The document references the company's initial public offering and the use of raised funds, focusing on the adjustment of investment projects funded by the raised capital. This type of document is typically classified as a Capital/Financing Update (CAP) because it provides updates on the use and reallocation of funds raised through financing activities. It is not a full annual or interim report, nor is it a simple announcement of a report publication. It is not related to board changes, voting results, or legal proceedings. Therefore, the best fit is Capital/Financing Update (CAP). The document length (4624 characters) supports it being a substantive announcement rather than a brief notice.
2017-04-16 Chinese
独立董事候选人声明（魏刚）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate confirming qualifications, independence, and compliance with regulatory requirements. It is a formal statement related to board membership candidacy, not a financial report, audit, or earnings release. It does not contain financial data or results, nor is it an announcement of voting results or a proxy solicitation. It is related to board/management information, specifically about a director candidate's qualifications and declarations. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on director candidacy, supporting this classification.
2017-04-16 Chinese
独立董事提名人声明（邹欣）
Regulatory Filings
2017-04-16 Chinese
平安证券股份有限公司关于普莱柯生物工程股份有限公司对部分暂时闲置募集资金和自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from Ping An Securities regarding the cash management of temporarily idle raised funds and the company's own funds by Pulike Bioengineering Co., Ltd. It references regulatory requirements, approvals, and internal controls related to the use of idle funds for cash management purposes. The document includes background on the fundraising, usage of funds, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor institution. It does not contain financial statements or quarterly/yearly financial results, nor is it a brief announcement or a certification letter. It is a specialized report focused on audit and regulatory compliance related to fund management, which fits the category of an Audit Report / Information (AR). The document length is 3061 characters, which is sufficient for a detailed report but not a full annual or interim report. Therefore, the best classification is AR with high confidence. FY 2016
2017-04-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.